What It Is
GHRP-2, also known as pralmorelin, is a synthetic six-amino-acid peptide (hexapeptide) that belongs to a class called growth hormone secretagogues.[1] It works by activating the ghrelin receptor (GHSR-1a), the same receptor targeted by the naturally occurring gut hormone ghrelin, which is best known for stimulating both growth hormone release and appetite.
GHRP-2 has one narrow, legitimate medical footprint: in Japan, it is used as an approved diagnostic agent — a growth hormone stimulation test for evaluating suspected growth hormone deficiency.[2] Outside that diagnostic context, GHRP-2 is sold only as an unapproved research chemical; it is not approved by the FDA for any general therapeutic or performance use in the United States.
How It Works
GH release is governed by three signals: GHRH (a hypothalamic "go" signal), somatostatin (a "brake" signal), and ghrelin/GHSR signaling (a second "go" signal). GHRP-2 mimics ghrelin at that third pathway, triggering pulses of growth hormone release rather than supplying growth hormone directly.[3]
Because it acts through the ghrelin receptor, GHRP-2 reliably increases hunger — an on-target consequence of the mechanism, not a side effect. Human studies also show it raises prolactin and stimulates ACTH and cortisol, engaging the stress-hormone axis alongside the growth hormone axis, unlike more selective secretagogues such as ipamorelin. Repeated or continuous exposure has also been shown to blunt the GH response over time (tachyphylaxis), so more frequent dosing does not straightforwardly produce more growth hormone.
What the Research Shows
Controlled human studies confirm GHRP-2 is a potent GH secretagogue and consistently increases food intake in a dose-dependent way — one study in lean men found participants ate roughly a third more after GHRP-2 than placebo. In diagnostic research, GHRP-2 testing has been compared against reference tests like the insulin tolerance test for evaluating GH deficiency.[4]
Evidence for meaningful outcomes beyond biomarkers is much weaker. A GH pulse is not the same as sustained GH exposure, and outcomes depend on downstream IGF-1 signaling, sleep, training, and nutrition. In one pediatric study, boosting endogenous GH secretion with an intranasal GHRP-2 spray in children with GH deficiency did not promote growth — a clear demonstration that stimulating a hormone biomarker does not guarantee a meaningful result. Critical reviews describe evidence for GH-related compounds as an ergogenic aid as weak.
Safety & Side Effects
The most consistent and well-documented effect is increased appetite, which is a central practical trade-off for anyone considering GHRP-2 for body-composition goals. Beyond that, human endocrine studies show it raises prolactin and stimulates ACTH/cortisol, meaning it is not a "clean" GH-only intervention.[5]
- Reliable increase in hunger and food intake
- Elevated prolactin and stimulated ACTH/cortisol (stress-axis spillover)
- Reported adverse events in FDA safety communications, including increased insulin requirement, infection, and pancreatitis in some contexts, though causality was not established
- Quality and purity risks from unregulated, compounded, or "research use only" sourcing
- Blunted response with continuous or overly frequent dosing (tachyphylaxis)
People with diabetes, pituitary disease, adrenal issues, or a history of pancreatitis face elevated theoretical risk given the hormones GHRP-2 engages, and there is no established long-term safety profile for regular use in healthy adults.
Regulatory Status
GHRP-2 is not FDA-approved for any indication in the United States. The FDA's orphan drug designation database lists pralmorelin hydrochloride as designated for detecting GH deficiency, but explicitly "not FDA approved" even for that diagnostic use domestically.[6] Its only real regulatory legitimacy is as an approved diagnostic test in Japan.
The FDA has separately flagged GHRP-2 (injectable and nasal forms) as a bulk substance that may present significant safety risks when compounded, citing impurity concerns and reports of serious adverse events. It is also on WADA's Prohibited List as a growth-hormone-releasing peptide, so it is a doping violation in tested sport regardless of medical framing.[7] Any GHRP-2 sold online is, by definition, an unapproved research chemical, not a regulated medicine.
GHRP-2 Compared to Other GH Secretagogues
GHRP-2 sits within a family of ghrelin receptor agonists that also includes ipamorelin and the oral small molecule MK-677 (ibutamoren). In comparative animal research, ipamorelin stimulated GH without raising ACTH/cortisol the way GHRP-2 did, suggesting GHRP-2 is less hormonally selective, though a cleaner profile does not by itself prove better outcomes.[8]
The clearest comparison is regulatory legitimacy: macimorelin (Macrilen), another ghrelin receptor agonist, is FDA-approved specifically for diagnosing adult growth hormone deficiency, while tesamorelin is FDA-approved through a different mechanism (a GHRH analog) for a narrow HIV-related indication. Across this compound family, approval has supported narrow diagnostic or disease-specific uses, not general enhancement claims.